INNA ZELTSER: Open Payments
NPI 1346675717 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,635 in 60 payments from 12 companies in 2025. Trend: 2023 $370 · 2024 $1,446 · 2025 $1,635
Food & beverage: $1,635
| Company | Payments | Amount |
|---|---|---|
| Ardelyx, Inc. | 14 | $355 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $272 |
| Aimmune Therapeutics, Inc. | 6 | $252 |
| Janssen Biotech, Inc. | 8 | $213 |
| Madrigal Pharmaceuticals | 6 | $192 |
| ABBVIE INC. | 9 | $172 |
| Phathom Pharmaceuticals, Inc. | 2 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Boston Scientific Corporation | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
Products named: IBSRELA, XIFAXAN, ZENPEP, TREMFYA, REZDIFFRA, LINZESS, VOQUEZNA, RINVOQ.
Industry payments across NY — which companies pay providers there.
